TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Purchases 8,400 Shares of Stock

TherapeuticsMD, Inc. (NASDAQ:TXMD) Director Tommy Thompson bought 8,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average price of $1.67 per share, with a total value of $14,028.00. Following the transaction, the director directly owned 23,179 shares in the company, valued at $38,708.93. The trade was a 56.84% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

TherapeuticsMD Price Performance

Shares of NASDAQ TXMD opened at $1.68 on Tuesday. The stock has a market capitalization of $19.44 million, a P/E ratio of -168.00 and a beta of 0.41. TherapeuticsMD, Inc. has a one year low of $0.70 and a one year high of $2.44. The firm’s 50 day simple moving average is $1.55 and its two-hundred day simple moving average is $1.27.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.01 earnings per share for the quarter. TherapeuticsMD had a net margin of 10.80% and a return on equity of 0.27%. The firm had revenue of $0.78 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of TherapeuticsMD in a report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, TherapeuticsMD presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Citadel Advisors LLC raised its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,273 shares of the company’s stock after acquiring an additional 19,073 shares during the quarter. Citadel Advisors LLC owned approximately 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.